Repinotan in Patients With Acute Ischemic Stroke

ClinicalTrials.gov ID: NCT00044915

Public ClinicalTrials.gov record NCT00044915. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic / Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke

Study identification

NCT ID: NCT00044915
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Bayer; Industry
Enrollment: 782 participants

Conditions and interventions

Conditions

Interventions

Repinotan HCl (BAYX3702) Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 30, 2000
Primary completion: Not listed
Completion: Aug 31, 2004
Last update posted: Jun 11, 2009

2000 – 2004

United States locations

U.S. sites: 28
U.S. states: 18
U.S. cities: 28

Facility	City	State	ZIP	Site status
Not listed	Los Angeles	California	90024-1777	—
Not listed	Oceanside	California	92056-4405	—
Not listed	San Diego	California	92103-8765	—
Not listed	San Jose	California	95124	—
Not listed	Boynton Beach	Florida	33435-6000	—
Not listed	Fort Lauderdale	Florida	33308	—
Not listed	Ocala	Florida	34471	—
Not listed	Tampa	Florida	33606	—
Not listed	Decatur	Georgia	30033	—
Not listed	Honolulu	Hawaii	96813-2413	—
Not listed	Des Moines	Iowa	50314	—
Not listed	Baltimore	Maryland	21224	—
Not listed	Robbinsdale	Minnesota	55422-2900	—
Not listed	Great Falls	Montana	59405	—
Not listed	Edison	New Jersey	08818-3903	—
Not listed	Ridgewood	New Jersey	07450	—
Not listed	New Hyde Park	New York	11040-1496	—
Not listed	Stony Brook	New York	11794	—
Not listed	Chapel Hill	North Carolina	27599-7065	—
Not listed	Winston-Salem	North Carolina	27103	—
Not listed	Cleveland	Ohio	44109-1998	—
Not listed	Portland	Oregon	97225	—
Not listed	Philadelphia	Pennsylvania	19107	—
Not listed	Upland	Pennsylvania	19013-3995	—
Not listed	Beaufort	South Carolina	29902-5472	—
Not listed	Chattanooga	Tennessee	37403-2112	—
Not listed	Houston	Texas	77030	—
Not listed	Bellevue	Washington	98004-4687	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 91 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00044915, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 11, 2009 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00044915 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →